References
- Kleihues P, Cavenee WK. In: Pathology and genetics of tumors of the nervous system. IARC Press, Lyon, France (2000).
- Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
- Biederer C, Ries S, Brandts CH et al. Replication-selective viruses for cancer therapy. J. Mol. Med.80, 163–175 (2002).
- Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science274, 373–376 (1996).
- Heise C, Sampson-Johannes A, Williams A et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med.3, 639–645 (1997).
- O'Shea CC, Johnson L, Bagus B et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell6, 611–623 (2004).
- McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther.2, S157–S160 (2003).
- Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med.6, 879–885 (2000).
- Chiocca EA, Abbed KM, Tatter S et al. A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther.10, 958–966 (2004).
- Xia ZJ, Chang JH, Zhang L et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng23, 1666–1670 (2004).
- O'Shea CC, Soria C, Bagus B et al. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell8, 61–74 (2005).
- Harrison D, Sauthoff H, Heitner S et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved – deletion of the viral E1B-19-kD gene increases the viral oncolytic effect. Hum. Gene Ther.12, 1323–1332 (2001).
- Sherr CJ. Cancer Cell cycles. Science274, 1672–1677 (1996).
- Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell56, 67–75 (1989).
- Putzer BM, Rumpf H, Rega S et al. E1A 12S and 13S of the transformation-defective adenovirus type 12 strain CS-1 inactivate proteins of the RB family, permitting transactivation of the E2F-dependent promoter. J. Virol.71, 9538–95348 (1997).
- Howe JA, Demers GW, Johnson DE et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol. Ther.2, 485–495 (2000).
- Fueyo J, Gomez-Manzano C, Alemany R et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene19, 2–12 (2000).
- Bauerschmitz GJ, Lam JT, Kanerva A et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res.62, 1266–1270 (2002).
- Fueyo J, Alemany R, Gomez-Manzano C et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl Cancer Inst.95, 652–660 (2003).
- Jiang H, Alemany R, Gomez-Manzano C et al. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia7, 723–729 (2005).
- Gomez-Manzano C, Balague C, Alemany R et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene23, 1821–1828 (2004).
- Cascallo M, Capella G, Mazo A et al. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res.63, 5544–5550 (2003).
- Ramachandra M, Rahman A, Zou A et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat. Biotech.19, 1035–1041 (2001).
- Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res.59, 1498–1504 (1999).
- Hallenbeck PL, Chang YN, Hay C et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther.10, 1721–1733 (1999).
- Rodriguez R, Schuur ER, Lim HY et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res.57, 2559–2563 (1997).
- Parr MJ, Manome Y, Tanaka T et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med.3, 1145–1149 (1997).
- Tsukuda K, Wiewrodt R, Molnar-Kimber K et al. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res.62, 3438–3447 (2002).
- Jakubczak JL, Ryan P, Gorziglia M et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res.63, 1490–1499 (2003).
- Hernandez-Alcoceba R, Pihalja M, Qian D et al. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum. Gene Ther.13, 1737–1750 (2002).
- Johnson L, Shen A, Boyle L et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell1, 325–337 (2002).
- Blasco MA. Telomeres and cancer: a tale with many endings. Curr. Opin. Genet. Dev.13, 70–76 (2003).
- Huang TG, Savontaus MJ, Shinozaki K et al. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther.10, 1241–1247 (2003).
- Zou W, Luo C, Zhang Z et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene23, 457–464 (2004).
- Kawashima T, Kagawa S, Kobayashi N et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin. Cancer Res.10, 285–292 (2004).
- Kim E, Kim JH, Shin HY et al. Ad-mTERT-δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther.14, 1415–1428 (2003).
- Komata T, Kanzawa T, Kondo Y et al. Telomerase as a therapeutic target for malignant gliomas. Oncogene21, 656–663 (2002).
- Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat. Rev. Drug Discov.2, 803–811 (2003).
- Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr. Cancer Drug Targets3, 391–405 (2003).
- Cuevas Y, Hernandez-Alcoceba R, Aragones J et al. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res.63, 6877–6884 (2003).
- Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene22, 2065–2072 (2003).
- Ruan H, Wang J, Hu L et al. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX. Neoplasia1, 431–437 (1999).
- Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther.9, 270–281 (2002).
- Xie D, Yin D, Tong X et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res.64, 1987–1996 (2004).
- Yamamoto M, Davydova J, Wang M et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology125, 1203–1218 (2003).
- Davydova J, Le LP, Gavrikova T et al. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res.64, 4319–4327 (2004).
- Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J. Clin. Pathol.57, 6–13 (2004).
- Holland EC. A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol. Pathol.28, 171–177 (2000).
- Kurihara H, Zama A, Tamura M et al. Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator. Gene Ther.7, 686–693 (2000).
- Vandier D, Rixe O, Besnard F et al. Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther.7, 1120–1126 (2000).
- Chen J, Bezdek T, Chang J et al. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res.58, 3504–3507 (1998).
- Morelli AE, Larregina AT, Smith-Arica J et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J. Gen. Virol.80, 571–583 (1999).
- Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science275, 1320–1323 (1997).
- Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl Acad. Sci. USA94, 3352–3356 (1997).
- Wickham TJ, Mathias P, Cheresh DA et al. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell73, 309–319 (1993).
- Seth P. In: Adenoviruses: Basic Biology to Gene Therapy. RG Landes Company, TX, USA (1999).
- Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv. Pharmacol.40, 137–206 (1997).
- Miller CR, Buchsbaum DJ, Reynolds PN et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res.58, 5738–5748 (1998).
- Einfeld DA, Schroeder R, Roelvink PW et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol.75, 11284–11291 (2001).
- Thomas CE, Edwards P, Wickham TJ et al. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J. Virol.76, 3452–3460 (2002).
- Dechecchi MC, Melotti P, Bonizzato A et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol.75, 8772–8780 (2001).
- Smith TA, Idamakanti N, Marshall-Neff J et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther.14, 1595–1604 (2003).
- Michael SI, Hong JS, Curiel DT et al. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther.2, 660–668 (1995).
- Wickham TJ, Tzeng E, Shears LL II et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol.71, 8221–8229 (1997).
- Einfeld DA, Brough DE, Roelvink PW et al. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol.73, 9130–9136 (1999).
- Wickham TJ. Targeting adenovirus. Gene Ther.7, 110–114 (2000).
- Vigne E, Mahfouz I, Dedieu JF et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol.73, 5156–5161 (1999).
- Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther.6, 1336–1339 (1999).
- Yoshida Y, Sadata A, Zhang W et al. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum. Gene Ther.9, 2503–2515 (1998).
- Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J. Virol.76, 6893–6899 (2002).
- Krasnykh V, Belousova N, Korokhov N et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol.75, 4176–4183 (2001).
- Belousova N, Korokhov N, Krendelshchikova V et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol.77, 11367–11377 (2003).
- McDonald GA, Zhu G, Li Y et al. Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector. J. Gene Med.1, 103–110 (1999).
- Kim M, Sumerel LA, Belousova N et al. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br. J. Cancer88, 1411–1416 (2003).
- Bello L, Francolini M, Marthyn P et al. αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery49, 380–389 (2001).
- Mori T, Arakawa H, Tokino T et al. Significant increase of adenovirus infectivity in glioma cell lines by extracellular domain of hCAR. Oncol. Res.11, 513–521 (1999).
- Asaoka K, Tada M, Sawamura Y et al. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor. J. Neurosurg.92, 1002–1008 (2000).
- Suzuki K, Fueyo J, Krasnykh V et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res.7, 120–126 (2001).
- Libermann TA, Nusbaum HR, Razon N et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature313, 144–147 (1985).
- McLendon RE, Wikstrand CJ, Matthews MR et al. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J. Histochem. Cytochem.48, 1103–1110 (2000).
- Kuan CT, Wikstrand CJ and Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer8, 83–96 (2001).
- van Beusechem VW, Mastenbroek DC, van den Doel PB et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther.10, 1982–1991 (2003).
- Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer7, 165–197 (2000).
- Morrison RS. Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. J. Biol. Chem.266, 728–734 (1991).
- Goldman CK, Rogers BE, Douglas JT et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res.57, 1447–1451 (1997).
- Rancourt C, Rogers BE, Sosnowski BA et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res.4, 2455–2461 (1998).
- Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev.73, 161–195 (1993).
- Murphy G, Atkinson S, Ward R et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. NY Acad. Sci.667, 1–12 (1992).
- Drapkin PT, O'Riordan CR, Yi SM et al. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J. Clin. Invest.105, 589–596 (2000).
- McCormick F. Future prospects for oncolytic therapy. Oncogene24, 7817–7819 (2005).
- Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res.6, 4908–4914 (2000).
- Rogulski KR, Wing MS, Paielli DL et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther.11, 67–76 (2000).
- Freytag SO, Paielli D, Wing M et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int. J. Radiat. Oncol. Biol. Phys.54, 873–885 (2002).
- Toth K, Tarakanova V, Doronin K et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3–11.6K) protein. Cancer Gene Ther.10, 193–200 (2003).
- Lamfers ML, Grill J, Dirven CM et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res.62, 5736–5742 (2002).
- Geoerger B, Grill J, Opolon P et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br. J. Cancer89, 577–584 (2003).
- Freytag SO, Stricker H, Pegg J et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res.63, 7497–7506 (2003).